Table 2.

Use of DPP4 inhibitors in patients with type 2 diabetes and renal function impairment

Drug	Comment
Alogliptin	Doses should be halved in moderate-to severe renal failure eGFR 30–50 mL/min/1.73 m2: halve doses eGFR < 30 mL/min/1.73 m2: quarter doses
Linagliptin	Dose adjustment is not needed
Sitagliptin	Doses should be halved in moderate-to severe renal failure Should be avoided in end-stage renal disease or hemodialysis
Sitagliptin	Doses should be halved in moderate-to severe renal failure eGFR 30–50 mL/min/1.73 m2: halve doses eGFR < 30 mL/min/1.73 m2: quarter doses
Vildagliptin	Doses should be halved in moderate-to severe renal failure Use with caution in end-stage renal disease or hemodialysis

eGFR estimated glomerular filtration rate